ADDRESS: Street, City, Country
PHONE: +(123) 456 789
E-MAIL: your-email@mail.com
Novo Nordisk alleges Lilly’s advertisements for Zepbound and Mounjaro mislead consumers by comparing the drugs with lower-dose versions of Wegovy and Ozempic.
imphoenix82
Eligible Medicare beneficiaries can now access Wegovy in both injection and oral forms for a monthly copayment of $50 through the programme, which will remain in place until the end of 2027.
imphoenix82
Novo Nordisk plans to begin a phase 3 development programme for zenagamtide in adults with type 2 diabetes during the second half of 2026.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 8447496924
HealthXploreIndia @2026. All Rights Reserved.
